Tracer library / [177Lu]Lu-DOTA-Affiline-22
[177Lu]Lu-DOTA-Affiline-22
Also written as [Lu-177]Lu-DOTA-Affiline-22
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated Affilin recombinant protein
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >95% | DOTA-Affiline-22 Navigo Proteins GmbH | 40147849 2025 J Nucl Med The DOTA-Affiline-22 was labeled at 55°C for 1 h. |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Navigo Proteins GmbH
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-Affiline-22, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40147849. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40147849: 'DOTA-Affiline-22 was kindly donated by Navigo Proteins GmbH'. Stage set/updated at stage 39 from PMID 40147849: 'Preclinical studies, including ex vivo biodistribution, SPECT/CT, and PET analyses, were performed in Wistar rats to evaluate how coinjection of a paraaminohippurate solution affects the renal uptake of various radiopharmaceuticals'.